Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
20 hedge funds and large institutions have $26.2M invested in Trillium Therapeutics Inc. in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
13% more capital invested
Capital invested by funds: $23.2M → $26.2M (+$2.98M)
23% less funds holding
Funds holding: 26 → 20 (-6)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$358K |
| 2 |
Morgan Stanley
New York
|
+$254K |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$240K |
| 4 |
Millennium Management
New York
|
+$55.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$693K |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$540K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$264K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$131K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$89K |
TRIL Hedge Fund Activity: Q3 2017 in Review
20 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2017, worth a combined $26.2M — up 13% from $23.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TRIL and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was AWM Investment Company, adding an estimated $358K. The largest seller was International Biotechnology Trust, exiting entirely with an estimated $693K sold.
- 20 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2017, down from 26 in Q2 2017.
- Funds reported $26.2M of Trillium Therapeutics Inc. stock for Q3 2017, up 13% quarter-over-quarter.
- 3 funds opened new Trillium Therapeutics Inc. positions in Q3 2017 and 8 closed out, a net change of -5 holders.
- The largest Trillium Therapeutics Inc. buyer in Q3 2017 was AWM Investment Company, an estimated $358K added.
- The largest Trillium Therapeutics Inc. seller in Q3 2017 was International Biotechnology Trust, an estimated $693K sold.
Based on aggregated 13F filings for Q3 2017.